Loading clinical trials...
Loading clinical trials...
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
This study is a randomised, double blinded clinical trial and will be undertaken in primary care and community sites across Australia and tertiary care centres in Sri Lanka. Following a 4-week active run-in period, eligible participants will be randomised to either dapagliflozin 10mg daily, or metformin XR 2000mg daily in a 1:1 ratio.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
The George Institute for Global Health
Sydney, New South Wales, Australia
The George Institute for Global Health
Brisbane, Queensland, Australia
Monash University
Melbourne, Victoria, Australia
National Hospital - Galle
Galle, Southern Province, Sri Lanka
National Hospital of Sri Lanka 1
Colombo, Sri Lanka
National Hospital of Sri Lanka 2
Colombo, Sri Lanka
Jaffna Teaching Hospital
Jaffna, Sri Lanka
Kandy National Hospital
Kandy, Sri Lanka
Start Date
January 1, 2023
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2026
Last Updated
December 20, 2024
994
ESTIMATED participants
Dapagliflozin
DRUG
Metformin
DRUG
Lead Sponsor
The George Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587